Loading...
Header Logo
Keywords
Last Name
Institution

Diego Cadavid MD

TitleInstructor
InstitutionUniversity of Massachusetts Medical School
DepartmentNeurology
AddressFulcrum Therapeutics
One Kendall Square, Suite B7102
Cambridge MA 02139
Phone617-599-0755
vCardDownload vCard
    Other Positions
    InstitutionUMMS - School of Medicine
    DepartmentNeurology


    Collapse Biography 
    Collapse education and training
    Pontifical Xavierian University, Bogota, , ColombiaMD

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Farley BJ, Morozova E, Dion J, Wang B, Harvey BD, Gianni D, Wipke B, Cadavid D, Wittmann M, Hajos M. Evoked potentials as a translatable biomarker to track functional remyelination. Mol Cell Neurosci. 2019 Jul 26; 103393. PMID: 31356882.
      View in: PubMed
    2. Cadavid D, Mellion M, Hupperts R, Edwards KR, Calabresi PA, Drulovic J, Giovannoni G, Hartung HP, Arnold DL, Fisher E, Rudick R, Mi S, Chai Y, Li J, Zhang Y, Cheng W, Xu L, Zhu B, Green SM, Chang I, Deykin A, Sheikh SI. Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2019 Jul 05. PMID: 31285147.
      View in: PubMed
    3. Weber JD, Smith E, Berry-Kravis E, Cadavid D, Hessl D, Erickson C. Voice of People with Fragile X Syndrome and Their Families: Reports from a Survey on Treatment Priorities. Brain Sci. 2019 Jan 23; 9(2). PMID: 30678024.
      View in: PubMed
    4. Klistorner A, Chai Y, Leocani L, Albrecht P, Aktas O, Butzkueven H, Ziemssen T, Ziemssen F, Frederiksen J, Xu L, Cadavid D. Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential. CNS Drugs. 2018 Sep 28. PMID: 30267385.
      View in: PubMed
    5. Cadavid D, Balcer L, Galetta S, Aktas O, Ziemssen T, Vanopdenbosch LJ, Leocani L, Freedman MS, Plant GT, Preiningerova JL, Ziemssen F, Massacesi L, Chai Y, Xu L. Predictors of response to opicinumab in acute optic neuritis. Ann Clin Transl Neurol. 2018 Oct; 5(10):1154-1162. PMID: 30349850.
      View in: PubMed
    6. Petrillo J, Balcer L, Galetta S, Chai Y, Xu L, Cadavid D. Initial Impairment and Recovery of Vision-Related Functioning in Participants With Acute Optic Neuritis From the RENEW Trial of Opicinumab. J Neuroophthalmol. 2018 Aug 07. PMID: 30095536.
      View in: PubMed
    7. Strzok S, Cleanthous S, Pompilus F, Cano SJ, Marquis P, Cohan S, Goldman MD, Kresa-Reahl K, Petrillo J, Castrillo-Viguera C, Cadavid D, Chen SY. Development of a gait module to complement the 12-item Multiple Sclerosis Walking Scale: a mixed methods study. Mult Scler J Exp Transl Clin. 2018 Apr-Jun; 4(2):2055217318783766. PMID: 30090638.
      View in: PubMed
    8. Cleanthous S, Strzok S, Pompilus F, Cano S, Marquis P, Cohan S, Goldman MD, Kresa-Reahl K, Petrillo J, Castrillo-Viguera C, Cadavid D, Chen SY. Addressing the targeting range of the ABILHAND-56 in relapsing-remitting multiple sclerosis: A mixed methods psychometric study. Mult Scler J Exp Transl Clin. 2018 Apr-Jun; 4(2):2055217318776990. PMID: 29796290.
      View in: PubMed
    9. Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurol. 2018 May; 17(5):405-415. PMID: 29545067.
      View in: PubMed
    10. Nolan RC, Galetta SL, Frohman TC, Frohman EM, Calabresi PA, Castrillo-Viguera C, Cadavid D, Balcer LJ. Optimal Intereye Difference Thresholds in Retinal Nerve Fiber Layer Thickness for Predicting a Unilateral Optic Nerve Lesion in Multiple Sclerosis. J Neuroophthalmol. 2018 Jan 29. PMID: 29384802.
      View in: PubMed
    11. Ranger A, Ray S, Szak S, Dearth A, Allaire N, Murray R, Gardner R, Cadavid D, Mi S. Anti-LINGO-1 has no detectable immunomodulatory effects in preclinical and phase 1 studies. Neurol Neuroimmunol Neuroinflamm. 2018 Jan; 5(1):e417. PMID: 29259995.
      View in: PubMed
    12. Fernández R, Cardona JA, Cadavid D, Álvarez LG, Restrepo FA. Survival of Endodontically Treated Roots/Teeth Based on Periapical Health and Retention: A 10-year Retrospective Cohort Study. J Endod. 2017 Dec; 43(12):2001-2008. PMID: 29061351.
      View in: PubMed
    13. Maranzano J, Rudko DA, Nakamura K, Cook S, Cadavid D, Wolansky L, Arnold DL, Narayanan S. MRI evidence of acute inflammation in leukocortical lesions of patients with early multiple sclerosis. Neurology. 2017 Aug 15; 89(7):714-721. PMID: 28724581.
      View in: PubMed
    14. Cadavid D, Balcer L, Galetta S, Aktas O, Ziemssen T, Vanopdenbosch L, Frederiksen J, Skeen M, Jaffe GJ, Butzkueven H, Ziemssen F, Massacesi L, Chai Y, Xu L, Freeman S. Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2017 Mar; 16(3):189-199. PMID: 28229892.
      View in: PubMed
    15. Cadavid D, Auwaerter PG, Rumbaugh J, Gelderblom H. Antibiotics for the neurological complications of Lyme disease. Cochrane Database Syst Rev. 2016 12 08; 12:CD006978. PMID: 27931077.
      View in: PubMed
    16. Goldman MD, Ward MD, Motl RW, Jones DE, Pula JH, Cadavid D. Identification and validation of clinically meaningful benchmarks in the 12-item Multiple Sclerosis Walking Scale. Mult Scler. 2017 Sep; 23(10):1405-1414. PMID: 27903937.
      View in: PubMed
    17. Brown RA, Narayanan S, Stikov N, Cook S, Cadavid D, Wolansky L, Arnold DL. MTR recovery in brain lesions in the BECOME study of glatiramer acetate vs interferon ß-1b. Neurology. 2016 Aug 30; 87(9):905-11. PMID: 27473139.
      View in: PubMed
    18. Cadavid D, Cohen JA, Freedman MS, Goldman MD, Hartung HP, Havrdova E, Jeffery D, Kapoor R, Miller A, Sellebjerg F, Kinch D, Lee S, Shang S, Mikol D. The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. Mult Scler. 2017 Jan; 23(1):94-105. PMID: 27003945.
      View in: PubMed
    19. Sellebjerg F, Cadavid D, Steiner D, Villar LM, Reynolds R, Mikol D. Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis. Ther Adv Neurol Disord. 2016 Jan; 9(1):31-43. PMID: 26788129; PMCID: PMC4710106.
      View in: PubMed, PubMed Central
    20. Galetta SL, Villoslada P, Levin N, Shindler K, Ishikawa H, Parr E, Cadavid D, Balcer LJ. Acute optic neuritis: Unmet clinical needs and model for new therapies. Neurol Neuroimmunol Neuroinflamm. 2015 Aug; 2(4):e135. PMID: 26236761; PMCID: PMC4516397.
      View in: PubMed, PubMed Central
    21. Magistrale G, Medori R, Cadavid D, Argento O, Incerti C, Pisani V, Caltagirone C, Bozzali M, DeLuca J, Nocentini U. Assessing clinical correlates of self-rated disability in patients with multiple sclerosis. Mult Scler J Exp Transl Clin. 2015 Jan-Dec; 1:2055217315592425. PMID: 28607696.
      View in: PubMed
    22. Motl RW, Putzki N, Pilutti LA, Cadavid D. Longitudinal changes in self-reported walking ability in multiple sclerosis. PLoS One. 2015; 10(5):e0125002. PMID: 25932911; PMCID: PMC4416760.
      View in: PubMed, PubMed Central
    23. Wolansky LJ, Cadavid D, Punia V, Kim S, Cheriyan J, Haghighi M, Cook SD. Hypophosphatemia is Associated with the Serial Administration of Triple-Dose Gadolinium to Patients for Brain MRI. J Neuroimaging. 2015 May-Jun; 25(3):379-83. PMID: 25867798.
      View in: PubMed
    24. Tran JQ, Rana J, Barkhof F, Melamed I, Gevorkyan H, Wattjes MP, de Jong R, Brosofsky K, Ray S, Xu L, Zhao J, Parr E, Cadavid D. Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033. Neurol Neuroimmunol Neuroinflamm. 2014 Aug; 1(2):e18. PMID: 25340070; PMCID: PMC4202679.
      View in: PubMed, PubMed Central
    25. Magistrale G, Pisani V, Argento O, Incerti CC, Bozzali M, Cadavid D, Caltagirone C, Medori R, DeLuca J, Nocentini U. Validation of the World Health Organization Disability Assessment Schedule II (WHODAS-II) in patients with multiple sclerosis. Mult Scler. 2015 Apr; 21(4):448-56. PMID: 25092769.
      View in: PubMed
    26. Londoño D, Cadavid D, Drouin EE, Strle K, McHugh G, Aversa JM, Steere AC. Antibodies to endothelial cell growth factor and obliterative microvascular lesions in the synovium of patients with antibiotic-refractory lyme arthritis. Arthritis Rheumatol. 2014 Aug; 66(8):2124-33. PMID: 24623727; PMCID: PMC4211115.
      View in: PubMed, PubMed Central
    27. Erlanger DM, Kaushik T, Caruso LS, Benedict RH, Foley FW, Wilken J, Cadavid D, Deluca J. Reliability of a cognitive endpoint for use in a multiple sclerosis pharmaceutical trial. J Neurol Sci. 2014 May 15; 340(1-2):123-9. PMID: 24656433.
      View in: PubMed
    28. Edwards KR, Goyal J, Plavina T, Czerkowicz J, Goelz S, Ranger A, Cadavid D, Browning JL. Feasibility of the use of combinatorial chemokine arrays to study blood and CSF in multiple sclerosis. PLoS One. 2013; 8(11):e81007. PMID: 24278364; PMCID: PMC3835751.
      View in: PubMed, PubMed Central
    29. Wattjes MP, Richert ND, Killestein J, de Vos M, Sanchez E, Snaebjornsson P, Cadavid D, Barkhof F. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy. Mult Scler. 2013 Dec; 19(14):1826-40. PMID: 24192217.
      View in: PubMed
    30. Goldman MD, Motl RW, Scagnelli J, Pula JH, Sosnoff JJ, Cadavid D. Clinically meaningful performance benchmarks in MS: timed 25-foot walk and the real world. Neurology. 2013 Nov 19; 81(21):1856-63. PMID: 24174581; PMCID: PMC3821712.
      View in: PubMed, PubMed Central
    31. Motl RW, Cadavid D, Sandroff BM, Pilutti LA, Pula JH, Benedict RH. Cognitive processing speed has minimal influence on the construct validity of Multiple Sclerosis Walking Scale-12 scores. J Neurol Sci. 2013 Dec 15; 335(1-2):169-73. PMID: 24104065.
      View in: PubMed
    32. Mi S, Pepinsky RB, Cadavid D. Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic. CNS Drugs. 2013 Jul; 27(7):493-503. PMID: 23681979.
      View in: PubMed
    33. Fernández R, Cadavid D, Zapata SM, Alvarez LG, Restrepo FA. Impact of three radiographic methods in the outcome of nonsurgical endodontic treatment: a five-year follow-up. J Endod. 2013 Sep; 39(9):1097-103. PMID: 23953279.
      View in: PubMed
    34. Learmonth YC, Motl RW, Sandroff BM, Pula JH, Cadavid D. Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis. BMC Neurol. 2013 Apr 25; 13:37. PMID: 23617555; PMCID: PMC3651716.
      View in: PubMed, PubMed Central
    35. Cadavid D, Jurgensen S, Lee S. Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis. PLoS One. 2013; 8(1):e53297. PMID: 23308186; PMCID: PMC3537666.
      View in: PubMed, PubMed Central
    36. Yousry TA, Pelletier D, Cadavid D, Gass A, Richert ND, Radue EW, Filippi M. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2012 Nov; 72(5):779-87. PMID: 23280794.
      View in: PubMed
    37. Orbach R, Zhao Z, Wang YC, O'Neill G, Cadavid D. Comparison of disease activity in SPMS and PPMS in the context of multicenter clinical trials. PLoS One. 2012; 7(10):e45409. PMID: 23049678; PMCID: PMC3462180.
      View in: PubMed, PubMed Central
    38. Johnson MA, Cadavid D. Simvastatin in acute optic neuritis. Mult Scler. 2012 Nov; 18(11):1657; author reply 1658. PMID: 22801929.
      View in: PubMed
    39. Benedict RH, Smerbeck A, Parikh R, Rodgers J, Cadavid D, Erlanger D. Reliability and equivalence of alternate forms for the Symbol Digit Modalities Test: implications for multiple sclerosis clinical trials. Mult Scler. 2012 Sep; 18(9):1320-5. PMID: 22277740.
      View in: PubMed
    40. Cheriyan J, Kim S, Wolansky LJ, Cook SD, Cadavid D. Impact of inflammation on brain volume in multiple sclerosis. Arch Neurol. 2012 Jan; 69(1):82-8. PMID: 22232347.
      View in: PubMed
    41. Qian P, Cadavid D, Wolansky LJ, Cook SD, Naismith RT. Heterogeneity in longitudinal evolution of ring-enhancing multiple sclerosis lesions. Ann Neurol. 2011 Oct; 70(4):668-9; author reply 669-70. PMID: 22028230; PMCID: PMC3489054.
      View in: PubMed, PubMed Central
    42. Cadavid D, Kim S, Peng B, Skurnick J, Younes M, Hill J, Wolansky LJ, Cook SD. Clinical consequences of MRI activity in treated multiple sclerosis. Mult Scler. 2011 Sep; 17(9):1113-21. PMID: 21613336.
      View in: PubMed
    43. Londoño D, Carvajal J, Strle K, Kim KS, Cadavid D. IL-10 Prevents apoptosis of brain endothelium during bacteremia. J Immunol. 2011 Jun 15; 186(12):7176-86. PMID: 21602495.
      View in: PubMed
    44. Tumani H, Cadavid D. Are high CSF levels of CXCL13 helpful for diagnosis of Lyme neuroborreliosis? Neurology. 2011 Mar 22; 76(12):1034-5. PMID: 21422454.
      View in: PubMed
    45. Gandhi G, Londoño D, Whetstine CR, Sethi N, Kim KS, Zückert WR, Cadavid D. Interaction of variable bacterial outer membrane lipoproteins with brain endothelium. PLoS One. 2010 Oct 22; 5(10):e13257. PMID: 21063459; PMCID: PMC2962627.
      View in: PubMed, PubMed Central
    46. Cadavid D, Tang Y, O'Neill G. [Responsiveness of the Expanded Disability Status Scale (EDSS) to disease progression and therapeutic intervention in progressive forms of multiple sclerosis]. Rev Neurol. 2010 Sep 16; 51(6):321-9. PMID: 20839168.
      View in: PubMed
    47. Londoño D, Cadavid D. Bacterial lipoproteins can disseminate from the periphery to inflame the brain. Am J Pathol. 2010 Jun; 176(6):2848-57. PMID: 20431027; PMCID: PMC2877846.
      View in: PubMed, PubMed Central
    48. Cadavid D. Spirochetal infections. Handb Clin Neurol. 2010; 96:179-219. PMID: 20109682.
      View in: PubMed
    49. Pachner AR, Cadavid D, Wolansky L, Skurnick J. Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study. Neurology. 2009 Nov 03; 73(18):1485-92. PMID: 19884576.
      View in: PubMed
    50. Mehra R, Londoño D, Sondey M, Lawson C, Cadavid D. Structure-function investigation of vsp serotypes of the spirochete Borrelia hermsii. PLoS One. 2009 Oct 30; 4(10):e7597. PMID: 19888463; PMCID: PMC2766631.
      View in: PubMed, PubMed Central
    51. Festa ED, Hankiewicz K, Kim S, Skurnick J, Wolansky LJ, Cook SD, Cadavid D. Serum levels of CXCL13 are elevated in active multiple sclerosis. Mult Scler. 2009 Nov; 15(11):1271-9. PMID: 19805441.
      View in: PubMed
    52. Lincoln JA, Cadavid D, Pollard J, McLeod J, Prineas J, Dowling P, Cook SD. We should use magnetic resonance imaging to classify and monitor the course of multiple sclerosis. Arch Neurol. 2009 Mar; 66(3):412-4. PMID: 19273765.
      View in: PubMed
    53. Londoño D, Carvajal J, Arguelles-Grande C, Marques A, Cadavid D. Interleukin 10 protects the brain microcirculation from spirochetal injury. J Neuropathol Exp Neurol. 2008 Oct; 67(10):976-83. PMID: 18800010; PMCID: PMC2712754.
      View in: PubMed, PubMed Central
    54. Londoño D, Marques A, Hornung RL, Cadavid D. Relapsing fever borreliosis in interleukin-10-deficient mice. Infect Immun. 2008 Dec; 76(12):5508-13. PMID: 18794280; PMCID: PMC2583564.
      View in: PubMed, PubMed Central
    55. Londoño D, Marques A, Hornung RL, Cadavid D. IL-10 helps control pathogen load during high-level bacteremia. J Immunol. 2008 Aug 01; 181(3):2076-83. PMID: 18641346; PMCID: PMC2793593.
      View in: PubMed, PubMed Central
    56. Cadavid D, Garcia E, Gelderblom H. Coinfection with Borrelia turicatae serotype 2 prevents the severe vestibular dysfunction and earlier mortality caused by serotype 1. J Infect Dis. 2007 Jun 01; 195(11):1686-93. PMID: 17471439.
      View in: PubMed
    57. Gelderblom H, Londoño D, Bai Y, Cabral ES, Quandt J, Hornung R, Martin R, Marques A, Cadavid D. High production of CXCL13 in blood and brain during persistent infection with the relapsing fever spirochete Borrelia turicatae. J Neuropathol Exp Neurol. 2007 Mar; 66(3):208-17. PMID: 17356382.
      View in: PubMed
    58. Gelderblom H, Schmidt J, Londoño D, Bai Y, Quandt J, Hornung R, Marques A, Martin R, Cadavid D. Role of interleukin 10 during persistent infection with the relapsing fever Spirochete Borrelia turicatae. Am J Pathol. 2007 Jan; 170(1):251-62. PMID: 17200198; PMCID: PMC1762696.
      View in: PubMed, PubMed Central
    59. Cadavid D. The mammalian host response to borrelia infection. Wien Klin Wochenschr. 2006 Nov; 118(21-22):653-8. PMID: 17160603.
      View in: PubMed
    60. Sethi N, Sondey M, Bai Y, Kim KS, Cadavid D. Interaction of a neurotropic strain of Borrelia turicatae with the cerebral microcirculation system. Infect Immun. 2006 Nov; 74(11):6408-18. PMID: 16940140; PMCID: PMC1695479.
      View in: PubMed, PubMed Central
    61. Cadavid D, Sondey M, Garcia E, Lawson CL. Residual brain infection in relapsing-fever borreliosis. J Infect Dis. 2006 May 15; 193(10):1451-8. PMID: 16619194.
      View in: PubMed
    62. Londoño D, Bai Y, Zückert WR, Gelderblom H, Cadavid D. Cardiac apoptosis in severe relapsing fever borreliosis. Infect Immun. 2005 Nov; 73(11):7669-76. PMID: 16239571; PMCID: PMC1273893.
      View in: PubMed, PubMed Central
    63. Wolansky LJ, Haghighi MH, Sevdalis E, Cook SD, Sethi N, Liu J, Joseph G, Tulloch K, Cadavid D. Safety of serial monthly administration of triple-dose gadopentetate dimeglumine in multiple sclerosis patients: preliminary results of the BECOME trial. J Neuroimaging. 2005 Jul; 15(3):289-90. PMID: 15951416.
      View in: PubMed
    64. Narayan K, Dail D, Li L, Cadavid D, Amrute S, Fitzgerald-Bocarsly P, Pachner AR. The nervous system as ectopic germinal center: CXCL13 and IgG in lyme neuroborreliosis. Ann Neurol. 2005 Jun; 57(6):813-23. PMID: 15929033.
      View in: PubMed
    65. Cadavid D, Bai Y, Hodzic E, Narayan K, Barthold SW, Pachner AR. Cardiac involvement in non-human primates infected with the Lyme disease spirochete Borrelia burgdorferi. Lab Invest. 2004 Nov; 84(11):1439-50. PMID: 15448708.
      View in: PubMed
    66. Mena H, Cadavid D, Rushing EJ. Human cerebral infarct: a proposed histopathologic classification based on 137 cases. Acta Neuropathol. 2004 Dec; 108(6):524-30. PMID: 15517310.
      View in: PubMed
    67. Pachner AR, Dail D, Bai Y, Sondey M, Pak L, Narayan K, Cadavid D. Genotype determines phenotype in experimental Lyme borreliosis. Ann Neurol. 2004 Sep; 56(3):361-70. PMID: 15349863.
      View in: PubMed
    68. Bai Y, Narayan K, Dail D, Sondey M, Hodzic E, Barthold SW, Pachner AR, Cadavid D. Spinal cord involvement in the nonhuman primate model of Lyme disease. Lab Invest. 2004 Feb; 84(2):160-72. PMID: 14688796.
      View in: PubMed
    69. Cadavid D, Bai Y, Dail D, Hurd M, Narayan K, Hodzic E, Barthold SW, Pachner AR. Infection and inflammation in skeletal muscle from nonhuman primates infected with different genospecies of the Lyme disease spirochete Borrelia burgdorferi. Infect Immun. 2003 Dec; 71(12):7087-98. PMID: 14638799; PMCID: PMC308929.
      View in: PubMed, PubMed Central
    70. Pachner AR, Dail D, Narayan K, Dutta K, Cadavid D. Increased expression of B-lymphocyte chemoattractant, but not pro-inflammatory cytokines, in muscle tissue in rhesus chronic Lyme borreliosis. Cytokine. 2002 Sep 21; 19(6):297-307. PMID: 12421572.
      View in: PubMed
    For assistance with using Profiles, please refer to the online tutorials or contact UMMS Help Desk or call 508-856-8643.
    Cadavid's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (252) concept(s)
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department